Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials

Comparative Efficacy of Bisphosphonates in Metastatic Breast and Prostate Cancer and Multiple Myeloma: A Mixed-Treatment Meta-analysis

(2013) C. Palmieri et al.   CLINICAL CANCER RESEARCH

Risk factors for renal impairment in patients with solid tumors or multiple myeloma treated with zoledronic acid

(2013) You Jin Cha et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial

(2013) Peter Barrett-Lee et al.   LANCET ONCOLOGY

Zoledronate for Metastatic Bone Disease and Pain: A Meta-Analysis of Randomized Clinical Trials

(2012) Min Zhu et al.   PAIN MEDICINE

Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis

(2012) Maria A. Lopez-Olivo et al.   SUPPORTIVE CARE IN CANCER

Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer

(2011) Filippo Francini et al.   International Journal of Clinical Oncology

Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer

(2009) P. HERAS et al.   EUROPEAN JOURNAL OF CANCER CARE

The Pharmacological Management of Skeletal-Related Events from Metastatic Tumors

(2009) Anna Hitron et al.   ORTHOPEDICS

Renal Toxicity following Zoledronic Acid Reversed with Ibandronate in a Prostate Cancer Patient with Bone Metastases

(2008) Timo K. Joensuu   UROLOGIA INTERNATIONALIS